VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Varicella Subunit Vaccine encoding gI and gE glycoproteins
Vaccine Information
  • Vaccine Name: Varicella Subunit Vaccine encoding gI and gE glycoproteins
  • Target Pathogen: Varicella-zoster virus
  • Target Disease: chickenpox / shingles
  • Vaccine Ontology ID: VO_0004153
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) (Kimura et al., 1998).
  • ORF67 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • ORF68 gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant: Freunds emulsified oil adjuvant
    • Adjuvant name: Freunds emulsified oil adjuvant
    • VO adjuvant ID: VO_0000133
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Guinea pig Response

  • Host Strain: Hartley
  • Vaccination Protocol: Female Hartley guinea pigs (5 weeks old) were immunized with either a mixture of purified re- combinant gE and gI (25 μg each) or the recombinant gE-gI complex (50 μg). Purified protein solutions (0.25 mL) were injected intramuscularly with 0.25 mL of complete Freund's adjuvant at the first injection followed with incomplete Freund's adjuvant at the second and third injections at 2-week intervals. Control animals received 0.25 mL of PBS and an equal amount of adjuvant (Kimura et al., 1998).
  • Challenge Protocol: To determine whether immunization with gE and gI can enhance the clearance of VZV in vivo, both immunized and control (adjuvant- alone) guinea pigs were challenged with VZV. Animals were inoculated intravitreally with 200 pfu of cell-associated VZV 4 weeks after the final immunization. At 4 h after inoculation, 4 animals from each group were sacrificed, and their eyes were harvested to test for infectious VZV (Kimura et al., 1998).
  • Efficacy: In the gE-gI-immunized group, VZV was isolated from only 1 of 4 animals, and this animal had the lowest CMI and the lowest titer of anti-gE and anti-gI antibodies in the vitreous body. In contrast, VZV was isolated from 3 of 4 animals in the adjuvant-alone group (Kimura et al., 1998).
References
Kimura et al., 1998: Kimura H, Wang Y, Pesnicak L, Cohen JI, Hooks JJ, Straus SE, Williams RK. Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis. The Journal of infectious diseases. 1998; 178(2); 310-317. [PubMed: 9697709].